These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

886 related articles for article (PubMed ID: 14555284)

  • 1. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery.
    Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN
    Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in T cell signal transduction by M. leprae antigens is associated with downregulation of second messengers PKC, calcium, calcineurin, MAPK and various transcription factors in leprosy patients.
    Chattree V; Khanna N; Rao DN
    Mol Immunol; 2007 Mar; 44(8):2066-77. PubMed ID: 17046060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal delivery of Mycobacterium leprae antigen(s) with murabutide and Trat peptide inhibits Fas-mediated apoptosis of peripheral blood mononuclear cells derived from leprosy patients.
    Chattree V; Khanna N; Bisht V; Rao DN
    Indian J Biochem Biophys; 2007 Oct; 44(5):386-93. PubMed ID: 18341215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients.
    Mutis T; Kraakman EM; Cornelisse YE; Haanen JB; Spits H; De Vries RR; Ottenhoff TH
    J Immunol; 1993 May; 150(10):4641-51. PubMed ID: 8482851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to Mycobacterium leprae is associated with defective expression of interleukin 2 receptors and is not reconstituted by interleukin 2.
    Mohagheghpour N; Gelber RH; Larrick JW; Sasaki DT; Brennan PJ; Engleman EG
    J Immunol; 1985 Aug; 135(2):1443-9. PubMed ID: 2989366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients.
    Shinde SR; Chiplunkar SV; Butlin R; Samson PD; Deo MG; Gangal SG
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):51-8. PubMed ID: 8326181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of apoptosis, activation of NKT cell and upregulation of CD40 and CD40L mediated by M. leprae antigen(s) combined with Murabutide and Trat peptide in leprosy patients.
    Chattree V; Khanna N; Bisht V; Rao DN
    Mol Cell Biochem; 2008 Feb; 309(1-2):87-97. PubMed ID: 18008143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae.
    Misra N; Murtaza A; Walker B; Narayan NP; Misra RS; Ramesh V; Singh S; Colston MJ; Nath I
    Immunology; 1995 Sep; 86(1):97-103. PubMed ID: 7590888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M. leprae and PPD-triggered T cell lines in tuberculoid and lepromatous leprosy.
    Shankar P; Agis F; Wallach D; Flageul B; Cottenot F; Augier J; Bach MA
    J Immunol; 1986 Jun; 136(11):4255-63. PubMed ID: 2422278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of Mycobacterium leprae.
    Gulle H; Schoel B; Chiplunkar S; Gangal S; Deo MG; Kaufmann SH
    Int J Lepr Other Mycobact Dis; 1992 Mar; 60(1):44-53. PubMed ID: 1602193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of proliferative response to M. leprae antigens in lepromatous T cells against candidate antileprosy vaccines.
    Mustafa AS
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):257-67. PubMed ID: 8862259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components.
    Ottenhoff TH; Converse PJ; Gebre N; Wondimu A; Ehrenberg JP; Kiessling R
    Eur J Immunol; 1989 Apr; 19(4):707-13. PubMed ID: 2659369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the presence of M. leprae reactive T lymphocytes in patients with lepromatous leprosy.
    Nath I; Sathish M; Jayaraman T; Bhutani LK; Sharma AK
    Clin Exp Immunol; 1984 Dec; 58(3):522-30. PubMed ID: 6391762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of host-protective (IFN-gamma), host-impairing (IL-10, IL-13) and inflammatory (TNF-alpha) cytokines by PBMC from leprosy patients stimulated with mycobacterial antigens.
    Machado P; Abrams J; Santos S; Brennan P; Barral A; Barral-Netto M
    Eur J Dermatol; 1998 Mar; 8(2):98-103. PubMed ID: 9649657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leprosy reactions: humoral and cellular immune responses to M. leprae, 65kDa, 28kDa, and 18 kDa antigens.
    Mohanty KK; Joshi B; Katoch K; Sengupta U
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):149-58. PubMed ID: 15301588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin.
    Barnass S; Mace J; Steele J; Torres P; Gervasoni B; Ravioli R; Terencio J; Rook GA; Waters MF
    Clin Exp Immunol; 1986 Apr; 64(1):41-9. PubMed ID: 2426020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of cell-mediated immune contrasuppression in lepromatous leprosy: modulation of a putative T contrasuppressor cell-subset.
    González-Amaro R; Salazar-González JF; Baranda L; Abud-Mendoza C; Moncada B; García R; Alcocer-Varela J
    Clin Exp Immunol; 1988 Mar; 71(3):399-404. PubMed ID: 3133142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo responses to Mycobacterium leprae: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions.
    Longley J; Haregewoin A; Yemaneberhan T; Warndorff van Diepen T; Nsibami J; Knowles D; Smith KA; Godal T
    Int J Lepr Other Mycobact Dis; 1985 Sep; 53(3):385-94. PubMed ID: 3900245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of delayed addition of antigen and 'E' rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy.
    Bahr GM; Rook GA; Stanford JL; Lydyard PM; Bryceson AD
    Immunology; 1981 Nov; 44(3):585-91. PubMed ID: 7033116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.